Diagnosis of Ovarian Cancer Using Decision Tree Classificationof Mass Spectral Data
Open Access
- 1 January 2003
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2003 (5) , 308-314
- https://doi.org/10.1155/s1110724303210032
Abstract
Recent reports from our laboratory and others support the SELDI ProteinChip technology as a potential clinical diagnostic tool when combined with n‐dimensional analyses algorithms. The objective of this study was to determine if the commercially available classification algorithm biomarker patterns software (BPS), which is based on a classification and regression tree (CART), would be effective in discriminating ovarian cancer from benign diseases and healthy controls. Serum protein mass spectrum profiles from 139 patients with either ovarian cancer, benign pelvic diseases, or healthy women were analyzed using the BPS software. A decision tree, using five protein peaks resulted in an accuracy of 81.5% in the cross‐validation analysis and 80%in a blinded set of samples in differentiating the ovarian cancer from the control groups. The potential, advantages, and drawbacks of the BPS system as a bioinformatic tool for the analysis of the SELDI high‐dimensional proteomic data are discussed.Keywords
Funding Information
- Gustavus and Louise Pfeiffer Research Foundation
- National Cancer Institute (CA85067)
This publication has 18 references indexed in Scilit:
- SELDI ProteinChip® Array Technology: Protein‐Based Predictive Medicine and Drug Discovery ApplicationsBioMed Research International, 2003
- SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosisExpert Review of Molecular Diagnostics, 2002
- Boosted Decision Tree Analysis of Surface-enhanced Laser Desorption/Ionization Mass Spectral Serum Profiles Discriminates Prostate Cancer from Noncancer PatientsClinical Chemistry, 2002
- Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast CancerClinical Chemistry, 2002
- Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.2002
- Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.2002
- Use of proteomic patterns in serum to identify ovarian cancerPublished by Elsevier ,2002
- Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in UrineThe American Journal of Pathology, 2001
- Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI‐TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast CancerDisease Markers, 2001
- Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixturesProstate Cancer and Prostatic Diseases, 1999